NCT03447470 2025-01-29Study to Evaluate the Safety and Tolerability of RXC004 in Advanced MalignanciesRedx Pharma LtdPhase 1 Completed46 enrolled 29 charts
NCT02859415 2022-04-05Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary MetastasesNational Institutes of Health Clinical Center (CC)Phase 1/2 Terminated3 enrolled 10 charts
NCT02420691 2020-10-30Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginM.D. Anderson Cancer CenterPhase 2 Completed21 enrolled 14 charts